Beijing Sailintai Pharmaceutical Technology

Beijing Sailintai Pharmaceutical Technology, also known as Centaurus BioPharma, is a prominent clinical-stage biotechnology company based in Beijing, China, and serves as the core research and development subsidiary of Shouyao Holdings (Beijing) Co., Ltd. (688197.SH). Founded in 2006, the company focuses on the discovery and development of innovative small molecule therapeutics, particularly in the fields of oncology and metabolic diseases. Its advanced pipeline features several high-potential candidates, including the recently approved ALK/FAK inhibitor Conteltinib (SY-707) and the third-generation ALK inhibitor Ficonalkib (SY-3505). Sailintai has established strategic collaborations with major pharmaceutical companies such as Chia Tai Tianqing (CTTQ) to accelerate the development and commercialization of its drug candidates. The company's robust R&D platform has produced over 20 innovative programs, positioning it as a significant contributor to the Chinese biopharmaceutical industry. With its parent company's successful IPO on the STAR Market, Sailintai continues to expand its manufacturing and clinical capabilities to bring affordable innovative medicines to patients.